AngioDynamics(ANGO) - 2023 Q1 - Earnings Call Presentation

Financial Performance - Revenue increased by 5.9% to $81.537 million in Q1 FY23 from $76.971 million in Q1 FY22 [8] - Med Tech revenue increased by 29.6% while Med Device revenue decreased by 1.1% [6] - Net loss was ($13.004) million in Q1 FY23, compared to ($6.972) million in Q1 FY22 [8] - Adjusted EPS was ($0.06) in Q1 FY23, compared to ($0.02) in Q1 FY22 [8] - Adjusted EBITDA was $2.961 million in Q1 FY23, compared to $3.570 million in Q1 FY22 [8] - Gross margin for Med Tech was 63.2%, a decrease of 220 bps, and for Med Device was 47.5%, a decrease of 70 bps [8] Product Performance - Auryon sales reached $8.8 million [6] - Mechanical Thrombectomy (AngioVac and AlphaVac) experienced a year-over-year growth of 36.1% [6] - AlphaVac sales amounted to $1.8 million [6] - NanoKnife disposables saw a year-over-year growth of 12.3% [6] Cash Flow - Cash decreased by $4.261 million from Q4 FY22 to $24.564 million in Q1 FY23 [16] - The company entered into a new credit facility including a $75.0 million revolving facility and a $30.0 million delayed-draw term loan [6]